奥美沙坦酯对链脲佐菌素诱导的糖尿病大鼠糖尿病肾病的肾脏保护作用。
Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.
作者信息
Si Xiaofei, Li Peng, Zhang Yan, Zhang Yan, Lv Wei, Qi Dong
机构信息
School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P.R. China.
Yantai Yu Huang Ding Hospital, Yantai, Shandong 264000, P.R. China.
出版信息
Biomed Rep. 2014 Jan;2(1):24-28. doi: 10.3892/br.2013.183. Epub 2013 Oct 9.
Olmesartan medoxomil (OM) is one of the newest members of the angiotensin receptor blocker (ARB) family. The renoprotective effects of the angiotensin II type 1 receptor antagonist OM was investigated in a streptozotocin (STZ)-induced diabetic rat model. In this study, we investigated whether OM was able to ameliorate diabetic nephropathy (DN). Thirty male Sprague Dawley rats were assigned to 3 groups: the non-diabetic (group A, n=10), the untreated STZ-induced DN control (group B, n=10) and the STZ-induced DN treated with OM (group C, n=10). Blood pressure (BP) and glucose, creatinine (Cr), blood urea nitrogen (BUN), superoxide dismutase (SOD), malondialdehyde (MDA) microalbumin and urinary protein concentrations were measured. In STZ diabetic rats, BP, glucose, Cr, BUN, MDA and urinary protein levels were significantly increased compared to the non-diabetic control group. OM significantly improved the biological indices in the DN rats. The renal pathological changes were also observed under a light microscope. Our results suggested that OM exerted renoprotective effects on rats with STZ-induced diabetes.
奥美沙坦酯（OM）是血管紧张素受体阻滞剂（ARB）家族的最新成员之一。在链脲佐菌素（STZ）诱导的糖尿病大鼠模型中研究了1型血管紧张素受体拮抗剂OM的肾脏保护作用。在本研究中，我们调查了OM是否能够改善糖尿病肾病（DN）。将30只雄性Sprague Dawley大鼠分为3组：非糖尿病组（A组，n = 10）、未治疗的STZ诱导的DN对照组（B组，n = 10）和用OM治疗的STZ诱导的DN组（C组，n = 10）。测量血压（BP）、血糖、肌酐（Cr）、血尿素氮（BUN）、超氧化物歧化酶（SOD）、丙二醛（MDA）、微量白蛋白和尿蛋白浓度。与非糖尿病对照组相比，STZ糖尿病大鼠的BP、血糖、Cr、BUN、MDA和尿蛋白水平显著升高。OM显著改善了DN大鼠的生物学指标。在光学显微镜下也观察到了肾脏病理变化。我们的结果表明，OM对STZ诱导的糖尿病大鼠具有肾脏保护作用。
Zotero 插件